Bradley Augustson

Early Mortality After Diagnosis of Multiple Myeloma: Analysis of Patients Entered Onto the United Kingdom Medical Research Council Trials Between 1980 and 2002—Medical Research Council Adult Leukaemia Working Party

Bradley Augustson, Gulnaz Begum, Janet Dunn et al. · Journal of Clinical Oncology · 2005 · 490 citations · Full text

Medicine, Hematology, Internal Medicine +10

Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis

Efstathios Kastritis, Xavier Leleu, Bertrand Arnulf et al. · Journal of Clinical Oncology · 2020 · 146 citations · Full text

Medicine, Oncology, Pharmacology +14

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

John C. Byrd, Stephen D. Smith, Nina D. Wagner‐Johnston et al. · Oncotarget · 2018 · 83 citations · Full text

Medicine, Hematology, Oncology +17

A Randomized Phase III Trial of Melphalan and Dexamethasone (MDex) Versus Bortezomib, Melphalan and Dexamethasone (BMDex) for Untreated Patients with AL Amyloidosis

Efstathios Kastritis, Xavier Leleu, Bertrand Arnulf et al. · Blood · 2016 · 62 citations

Pharmacy, Pharmacology, Pharmacotherapy +8

COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study

Allison Barraclough, Musa Alzahrani, Marianne Schmidt Ettrup et al. · Blood Advances · 2019 · 52 citations · Full text

Medicine, Hematology, Oncology +17